
Leila Mousavifar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8228508/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Aberrant glycosylation patterns on cancer cells: Therapeutic opportunities for glycodendrimers/metallodendrimers oncology. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1659.	6.1	12
2	Design, Synthetic Strategies, and Therapeutic Applications of Heterofunctional Glycodendrimers. Molecules, 2021, 26, 2428.	3.8	17
3	Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes. International Journal of Molecular Sciences, 2021, 22, 7996.	4.1	4
4	Recent Development in the Design of Neoglycoliposomes Bearing Arborescent Architectures. Molecules, 2021, 26, 4281.	3.8	2
5	Recent development in the design of small â€~drug-like' and nanoscale glycomimetics against Escherichia coli infections. Drug Discovery Today, 2021, 26, 2124-2137.	6.4	10
6	Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposome. International Journal of Pharmaceutics, 2021, 606, 120849.	5.2	8
7	The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting. International Journal of Environmental Research and Public Health, 2020, 17, 5648.	2.6	49
8	Comparative Study of Aryl O-, C-, and S-Mannopyranosides as Potential Adhesion Inhibitors toward Uropathogenic E. coli FimH. Molecules, 2019, 24, 3566.	3.8	8
9	Deciphering the conformation of C-linked $\hat{I}\pm$ -D-mannopyranosides and their application toward the synthesis of low nanomolar E. coli FimH ligands. Arkivoc, 2019, 2018, 384-397.	0.5	2
10	Development of Mannopyranoside Therapeutics against Adherent-Invasive <i>Escherichia coli</i> Infections. Accounts of Chemical Research, 2018, 51, 2937-2948.	15.6	23
11	Sites for Dynamic Protein-Carbohydrate Interactions of O- and C-Linked Mannosides on the E. coli FimH Adhesin. Molecules, 2017, 22, 1101.	3.8	23